Free Trial
NASDAQ:DNTH

Dianthus Therapeutics Q1 2025 Earnings Report

Dianthus Therapeutics logo
$18.13 -0.21 (-1.15%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$18.11 -0.02 (-0.08%)
As of 06/26/2025 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dianthus Therapeutics EPS Results

Actual EPS
-$0.82
Consensus EPS
-$0.86
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Dianthus Therapeutics Revenue Results

Actual Revenue
$1.16 million
Expected Revenue
$0.81 million
Beat/Miss
Beat by +$356.00 thousand
YoY Revenue Growth
N/A

Dianthus Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Dianthus Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Dianthus Therapeutics Earnings Headlines

DNTH - Dianthus Therapeutics Inc Dividends - Morningstar
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
See More Dianthus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email.

About Dianthus Therapeutics

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

View Dianthus Therapeutics Profile

More Earnings Resources from MarketBeat